US Renal Disease Market Overview:
As per MRFR analysis, the US Renal Disease Market Size was estimated at 756 (USD Million) in 2023. The US Renal Disease Market Industry is expected to grow from 850(USD Million) in 2024 to 2,100 (USD Million) by 2035. The US Renal Disease Market CAGR (growth rate) is expected to be around 8.57% during the forecast period (2025 - 2035).
Key US Renal Disease Market Trends Highlighted
The US Renal Disease Market is currently experiencing several significant trends driven by both demographic and technological factors. One of the key market drivers is the increasing prevalence of renal diseases, particularly due to rising rates of diabetes and hypertension among the US population. As more individuals are diagnosed with chronic kidney disease (CKD), there is a growing demand for effective treatment options, including dialysis and kidney transplants. This has led to more innovations in treatment modalities, improving patient outcomes and quality of life. Opportunities for growth within the market also emerge from advancements in telemedicine and home-based therapies.Patients are increasingly seeking alternatives to in-clinic treatments, and this trend provides a chance for companies to develop and offer more remote monitoring solutions and home dialysis options. The shift towards personalized medicine is another noteworthy trend, which allows for treatments tailored to the individual needs of patients based on their unique medical profiles. In recent times, there has been a heightened focus on value-based care and improving patient engagement. Healthcare providers in the US are actively working to enhance patient experience and outcomes, incentivizing better management of renal disease. Additionally, federal initiatives aimed at improving kidney care, such as the Advancing American Kidney Health initiative, emphasize the significance of early detection and preventive measures, further shaping the market landscape.These trends signify a transformative phase in the US Renal Disease Market, driven by evolving patient needs and innovative solutions.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
US Renal Disease Market Drivers
Increasing Prevalence of Chronic Kidney Disease
Chronic Kidney Disease (CKD) has become increasingly prevalent across the United States, with nearly 15% of the adult population affected, according to the Centers for Disease Control and Prevention (CDC). This rising incidence is primarily attributed to the growing rates of diabetes and hypertension, which are major risk factors for CKD. Specifically, the CDC indicates that diabetes is expected to affect approximately 30.3 million individuals in the US by 2035, significantly elevating the demand for effective renal disease management and treatment options.As the US Renal Disease Market Industry faces a higher patient volume, there is a clear impetus for stakeholders to enhance their services and product offerings, leading to market growth. Moreover, organizations such as the National Kidney Foundation play a crucial role in raising awareness and advocating for better healthcare practices, which further fuels the market expansion.
Advancements in Renal Replacement Therapies
The US Renal Disease Market industry has been significantly impacted by recent advancements in renal replacement therapies, notably dialysis and kidney transplantation. According to the United States Renal Data System, there were approximately 780,000 individuals undergoing dialysis or living with a functioning kidney transplant in the US as of 2020, and this number continues to rise as treatment methods improve. With organizations like the American Society of Nephrology promoting Research and Development (R&D) in innovative dialysis technologies, such as portable dialysis machines, the market is set to benefit from increased patient accessibility and improved treatment efficacy, leading to an expansion in the patient base and subsequent market growth.
Government Initiatives and Funding for Renal Care
The US government has taken substantial steps to improve renal care through policy initiatives and funding opportunities. For instance, programs like the End-Stage Renal Disease (ESRD) Quality Incentive Program aim to enhance the quality of care for patients requiring dialysis treatment. According to the Centers for Medicare & Medicaid Services, government expenditures on renal healthcare surpassed $33 billion in 2020, a figure projected to grow as the population ages and chronic conditions become more prevalent.Such funding directly impacts the US Renal Disease Market industry by ensuring financial support for healthcare providers and enabling them to invest in new technologies and improved patient care methods.
US Renal Disease Market Segment Insights:
Renal Disease Market Type Insights
The US Renal Disease Market encompasses a diverse landscape shaped by various types, primarily focusing on Chronic Kidney Disease (CKD) and End-Stage Renal Disease (ESRD). Chronic Kidney Disease remains a profound concern in the US, substantially impacting millions of individuals, leading to its classification as a critical public health challenge. The prevalence of CKD has been on the rise due to factors such as diabetes and hypertension, necessitating enhanced management and treatment options to support patients throughout their disease trajectory. The US Renal Disease Market statistics show a significant portion of healthcare spending directed towards CKD management, reflecting its economic burden on the healthcare system.End-Stage Renal Disease is particularly critical as it represents the advanced stage of kidney disease where patients typically require interventions such as dialysis or kidney transplantation to extend their lives. This condition is associated with a host of complications, further driving demand for specialized healthcare services and advanced therapies. The growing aging population in the United States contributes to the rising prevalence of ESRD, as older adults are more susceptible to kidney-related ailments, thus amplifying the opportunities within the market.The market growth surrounding these types is driven by increasing awareness about kidney health, along with advances in medical technology that facilitate better diagnosis and treatment options. There is also a noteworthy push towards preventive healthcare, aiming to reduce the burden of chronic diseases, including CKD. With a significant investment in research and development, institutions are increasingly focusing on innovative therapies and patient-centric care approaches to mitigate the progression of kidney disease and enhance the quality of life for affected individuals.Opportunities also arise from ongoing initiatives encouraging routine screening and early detection of renal diseases, crucial for managing CKD effectively and potentially averting ESRD. However, challenges persist, such as disparities in access to care and socioeconomic factors influencing patient outcomes. Improving healthcare policies, fostering education on kidney diseases, and ensuring equitable access to treatment and preventive measures are essential steps to address these challenges within the US Renal Disease Market.The segmentation of the US Renal Disease Market highlights the overarching importance of Type segmentation in elucidating treatment pathways and healthcare strategies focused on managing renal diseases. By concentrating resources and efforts on both Chronic Kidney Disease and End-Stage Renal Disease, stakeholders can optimize patient care and resource allocation, thereby contributing to improved overall health outcomes in the US population.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Renal Disease Market Treatment Insights
The Treatment segment of the US Renal Disease Market encompasses critical methods that address kidney-related health issues among patients. This segment is characterized by key approaches including Dialysis, Medication, and Kidney Transplantation. Dialysis remains a predominant option due to the growing prevalence of chronic kidney disease, necessitating life-sustaining treatment for many individuals. Medication plays a vital role in managing various conditions associated with renal diseases, such as hypertension and anemia, and is essential for improving patients' quality of life.Additionally, Kidney Transplantation stands out as a long-term treatment solution that can significantly enhance survival rates and reduce healthcare costs associated with ongoing dialysis. The US Renal Disease Market presents opportunities driven by advancements in technology, increased healthcare expenditures, and rising awareness regarding kidney health. However, challenges such as the high costs of treatments and limited availability of donor organs for transplantation persist. Valuable insights from the US Renal Disease Market data emphasize the dynamic nature of treatment options available and their potential impact on patient outcomes as healthcare providers adapt to evolving patient needs and technological advancements in renal care.As the market develops, ongoing Research and Development initiatives are expected to foster innovation in treatment methodologies, ultimately benefiting those affected by renal diseases.
Renal Disease Market End User Insights
The US Renal Disease Market reflects significant growth driven by a diverse array of end users, primarily including Dialysis Centers, Hospitals and Clinics, as well as Research and Academic Institutes. Dialysis Centers play a crucial role in providing specialized care for patients with renal disease, making them a dominant force in patient treatment and management. The increasing prevalence of chronic kidney conditions enhances the reliance on these centers for effective management and treatment. Hospitals and Clinics also serve as critical access points for patients seeking multidisciplinary care, contributing significantly to market dynamics by facilitating comprehensive treatment plans and patient monitoring.Research and Academic Institutes are essential for advancing the understanding of renal diseases, driving innovation, and developing new treatment modalities, which contributes to market growth. The overall emphasis on improving patient outcomes and fostering research initiatives positions the end user segment as a vital component in the US Renal Disease Market, sustaining the momentum of advancements and care methodologies. As the market evolves, the integration of technology in these environments holds promise for enhancing efficiency and improving patient management in the realm of renal diseases.
US Renal Disease Market Key Players and Competitive Insights:
The US Renal Disease Market is a critical sector that addresses the increasing prevalence of kidney-related ailments, particularly chronic kidney disease and end-stage renal disease. As the demand for renal therapies and interventions rises, the competitive landscape is shaped by various players ranging from biotechnology firms to dialysis service providers. The market is characterized by innovations in treatment options, including pharmacological therapies, and improvements in dialysis technologies. Research and development efforts have intensified, driving the emergence of novel therapies aimed at better patient outcomes and enhanced quality of life for individuals suffering from renal diseases. Market players are continually exploring strategic collaborations, partnerships, and acquisitions to strengthen their market positions while navigating regulatory challenges and the need for cost-effective solutions.NantKwest has carved out a notable presence in the US Renal Disease Market with its focus on immunotherapy products and its innovative approach towards kidney diseases. The company's strengths lie in its dedication to research and development, which allows it to remain at the forefront of advancing treatment options. NantKwest's robust pipeline of investigational therapies demonstrates potential efficacy in renal-related conditions, creating optimistic prospects for patients who have limited options. The integration of cutting-edge technology and a strong emphasis on clinical trials augment its position, allowing it to leverage competitive advantages in a market that is constantly evolving. Furthermore, NantKwest’s commitment to forging partnerships enhances its capabilities and reach, ultimately aiming to deliver transformative treatments within the renal disease sector.American Renal Associates stands out in the US Renal Disease Market with a prominent focus on providing high-quality dialysis services. The company operates a substantial network of outpatient dialysis facilities across the country, delivering essential care to patients with chronic kidney disease. American Renal Associates focuses on personalized patient care and builds strong relationships with their dialysis patients, contributing to superior patient satisfaction and adherence to treatment protocols. Key services include in-center hemodialysis, home dialysis, and related renal services. The company has also pursued strategic growth through mergers and acquisitions, enabling it to expand its facility footprint and enhance operational efficiencies. With a commitment to improving patient outcomes, American Renal Associates continues to leverage its extensive market presence and specialized expertise to solidify its leadership position in this crucial segment of the healthcare landscape.
Key Companies in the US Renal Disease Market Include:
NantKwest
American Renal Associates
Medtronic
Fresenius Medical Care
Otsuka Pharmaceutical
Baxter International
Eisai
U.S. Renal Care
DaVita Inc
Astellas Pharma
AbbVie
Chugai Pharmaceutical
Avita Medical
Keryx Biopharma
Rockwell Medical
US Renal Disease Market Industry Developments
Recent developments in the US Renal Disease Market have set a dynamic tone for the sector, with significant initiatives and advancements. For instance, in August 2023, DaVita Inc announced a partnership with Fresenius Medical Care to enhance patient care. The collaboration aims at integrating innovative treatment modalities and improving patient outcomes. Furthermore, in July 2023, American Renal Associates reported a notable increase in its quarterly earnings and projected growth, demonstrating a strengthening financial position within the market. Additionally, U.S. Renal Care has been expanding its facilities and services throughout various states, highlighting a growing demand for renal care services. In the context of mergers and acquisitions, Otsuka Pharmaceutical completed the acquisition of Keryx Biopharma in September 2023, which adds valuable assets to their portfolio focused on renal solutions. Over the past two years, companies such as Baxter International and AbbVie have invested heavily in Research and Development to innovate treatments for renal disease, particularly considering the rise in diabetes-related kidney conditions in the US. With a projected valuation growth, the US Renal Disease Market is increasingly robust, driven by evolving treatment protocols and enhanced collaborations among leading companies.
US Renal Disease Market Segmentation Insights
Renal Disease Market Type Outlook
Chronic Kidney Disease
End-Stage Renal Disease
Renal Disease Market Treatment Outlook
Dialysis
Medication
Kidney Transplantation
Renal Disease Market End User Outlook
Dialysis Centers
Hospital & Clinics
Research and Academic Institutes
Report Scope:
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 756.0(USD Million) |
| MARKET SIZE 2024 | 850.0(USD Million) |
| MARKET SIZE 2035 | 2100.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.57% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | NantKwest, American Renal Associates, Medtronic, Fresenius Medical Care, Otsuka Pharmaceutical, Baxter International, Eisai, U.S. Renal Care, DaVita Inc, Astellas Pharma, AbbVie, Chugai Pharmaceutical, Avita Medical, Keryx Biopharma, Rockwell Medical |
| SEGMENTS COVERED | Type, Treatment, End User |
| KEY MARKET OPPORTUNITIES | Telemedicine for renal consultations, Advanced dialysis technology innovations, Home-based kidney disease management, Personalized medicine approaches, Kidney transplant optimization solutions |
| KEY MARKET DYNAMICS | aging population, increasing diabetes prevalence, rising healthcare costs, advances in treatment options, growing awareness of renal health |
| COUNTRIES COVERED | US |
Frequently Asked Questions (FAQ) :
The US Renal Disease Market is expected to be valued at 850.0 million USD in 2024.
The expected compound annual growth rate (CAGR) for the US Renal Disease Market from 2025 to 2035 is 8.57%.
The market for Chronic Kidney Disease is valued at 500.0 million USD in 2024.
The market for End-Stage Renal Disease is projected to reach 900.0 million USD by 2035.
Major players in the market include Medtronic, Fresenius Medical Care, Baxter International, and DaVita Inc.
By 2035, the overall US Renal Disease Market is expected to be valued at 2100.0 million USD.
The Chronic Kidney Disease segment is expected to show significant growth, reaching approximately 1200.0 million USD by 2035.
Key growth drivers include increasing prevalence of renal diseases and advancements in treatment technologies.
The Chronic Kidney Disease segment has a larger market share compared to the End-Stage Renal Disease segment in both 2024 and 2035.
There are opportunities for innovation in treatment options and improvements in patient care management within the US Renal Disease Market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
